HMG-CoA reductase / NPC1L1 drugs for Atherosclerotic Cardiovascular Disease
4 tracked HMG-CoA reductase / NPC1L1 drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the HMG-CoA reductase / NPC1L1 page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
1 approved / phase 41 Phase 32 preclinical / unstaged
Head-to-head evidence: AG2304 vs Atozet (ezetimibe/atorvastatin) · AG2304 vs Ezetimibe/simvastatin (Vytorin) · AG2304 vs Rosuvamibe · Atozet (ezetimibe/atorvastatin) vs Ezetimibe/simvastatin (Vytorin) · Ezetimibe/simvastatin (Vytorin) vs Rosuvamibe